Media centre
Press releases
26/08/2003
Antisoma to de-list from Nasdaq Europe because of forthcoming closure of market
26 August 2003, London, UK: Antisoma (LSE: ASM- Nasdaq Europe: ASOM), the UK-based biopharmaceutical company, today announces that it has received approval for a voluntary de-listing from the Nasdaq Europe Market. The de-listing of Antisoma shares will be effective from the close of business on Wednesday 10 September 2003. The decision to de-list follows the announcement by Nasdaq Europe of its intention to close by the end of November 2003.
Following the de-listing, all Antisoma shares will continue to be traded on the London Stock Exchange, where the majority of trading takes place at present. Existing shareholders will not have to take any action to transfer their shareholdings. Importantly, they will not incur any additional costs as a result of the de-listing.
Antisoma will continue to provide its shareholders with press releases and related company information on www.antisoma.com.
Enquiries:
| Antisoma plc | +44 (0)20 8799 8200 | |
| Raymond Spencer, Chief Financial Officer | ||
| Financial Dynamics: | +44 (0)7884 238952 | |
| Jonathan Birt | ||
|
This page includes links to documents in Portable Document File (PDF) format. To read PDF documents you may need to download the free Adobe Acrobat Reader. For PDF accessibility help, visit Access Adobe. These links will open in a new browser window. |
Back to top